Hochtaunus-Kliniken gGmbH
- Address
- lock Available on a paid plan
Hochtaunus-Kliniken gGmbH - Gynecological Oncology Research Center
Hochtaunus-Kliniken gGmbH is a specialized clinical research facility focused on advancing treatment protocols for gynecological malignancies. The center demonstrates particular expertise in evaluating novel combination therapies involving immunotherapy, targeted therapy, and anti-angiogenic agents across a comprehensive spectrum of women's cancers.
- Advanced ovarian, fallopian tube, and peritoneal cancer treatment protocols combining bevacizumab, PARP inhibitors (niraparib, olaparib), and immunotherapy agents
- Recurrent and metastatic cervical carcinoma research utilizing checkpoint inhibitors with chemotherapy and bevacizumab combinations
- Advanced and recurrent endometrial cancer studies incorporating mismatch repair status and microsatellite instability biomarkers
- Rare gynecological malignancies including vulvar cancer treatment with novel immunotherapy-tyrosine kinase inhibitor combinations
The research program emphasizes precision medicine approaches with biomarker-driven patient selection, including homologous recombination deficiency testing and DNA mismatch repair status determination. The center participates in international phase III trials evaluating both progression-free survival and overall survival outcomes, with particular focus on maintenance therapy strategies and combination regimens that integrate chemotherapy, immunotherapy, and targeted molecular agents for patients with newly diagnosed and recurrent gynecological cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AGO Research GmbH2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AGO Research GmbH2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hochtaunus-Kliniken gGmbH
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy | Gilead Sciences Inc. | Phase III | Not Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 3 | Unknown | 2018-10-02 | 2022-08-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.